Lymphoma Clinical Trials in Chicago

Showing 281-300 of 306 trials

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

NCT00006345

RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.

Drug/Agent Toxicity by Tissue/OrganLymphoma

Ligand PharmaceuticalsStarted Nov 1999

Miami, Florida, United States • Chicago, Illinois, United States • New Orleans, Louisiana, United States +8 more locations

COMPLETEDPHASE12.2 miles

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

NCT00849654

The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.

B-Cell LymphomaB-Cell Leukemia

Pharmacyclics LLC.66 participantsStarted Feb 2009

Palo Alto, California, United States • Chicago, Illinois, United States • Bethesda, Maryland, United States +6 more locations

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Lymphoma Trials in Other Cities

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

506U78 in Treating Patients With Lymphoma

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

Other Conditions in Chicago